DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Radotinib is an investigational drug.
There have been 7 clinical trials for Radotinib. The most recent clinical trial was a Phase 3 trial, which was initiated on December 14th 2018.
The most common disease conditions in clinical trials are Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, and Leukemia. The leading clinical trial sponsors are Il-Yang Pharm. Co., Ltd., Asan Medical Center, and Ulsan University Hospital.
There are one hundred and four US patents protecting this investigational drug and one international patent.
Recent Clinical Trials for Radotinib
|Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease||Il-Yang Pharm. Co., Ltd.||Phase 2|
|Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE)||Il-Yang Pharm. Co., Ltd.||Phase 3|
|A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Resistance/Intolerance to Previous TKIs||Il-Yang Pharm. Co., Ltd.||Phase 3|
Top disease conditions for Radotinib
Top clinical trial sponsors for Radotinib
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Radotinib||Try Before You Buy||Pyrrolidinone derivatives as MetAP-2 inhibitors||Merck Patent GmbH (Darmstadt, DE)||Try Before You Buy|
|Radotinib||Try Before You Buy||.beta.-substituted .beta.-amino acids and analogs as chemotherapeutic agents and uses thereof||Quadriga Biosciences, Inc. (Los Altos, CA)||Try Before You Buy|
|Radotinib||Try Before You Buy||Heteroaryl compounds as IRAK inhibitors and uses thereof||Merck Patent GmbH (Darmstadt, DE)||Try Before You Buy|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Radotinib||Argentina||AR101414||2034-08-04||Try Before You Buy|
|Radotinib||Australia||AU2015299431||2034-08-04||Try Before You Buy|
|Radotinib||Brazil||BR112017000730||2034-08-04||Try Before You Buy|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|